FDA Approves Tauklarify for Tau PET Imaging in Alzheimer's Disease Assessment

　　In August 2026,the U.S.Food and Drug Administration(FDA)approved Tauklarify(generic name:florquinitau F-18 injection;development code:MK-6240),a novel tau-targeting radioactive diagnostic agent developed by Lantheus.The drug is indicated for adult patients with cognitive impairment who are being evaluated for Alzheimer's disease(AD),to assist in the detection of tau neurofibrillary tangles in the brain via positron emission tomography(PET)imaging.

　　It is important to note that Tauklarify is a diagnostic radiopharmaceutical.It provides imaging information to help clinicians assess tau pathology in the brain and is not a treatment for Alzheimer's disease.

　　Approved Indication and Limitations of Use

　　Tauklarify is approved for brain PET imaging in adult patients with cognitive impairment undergoing evaluation for Alzheimer's disease,to assist in identifying tau neurofibrillary tangle pathology.The FDA specified that Tauklarify PET results should not be used as a standalone basis for diagnosing Alzheimer's disease.A positive result indicates the presence of tau-related pathological signal but cannot independently confirm disease status or severity.A negative result does not fully exclude disease.Interpretation must be made in conjunction with clinical symptoms,cognitive assessments,and other medical findings by qualified physicians.

　　Clinical Evidence

　　The FDA approval was based on clinical study data evaluating Tauklarify tau PET imaging.Key endpoints included the ability of florquinitau F-18 PET imaging to detect tau protein deposition in the brain,inter-reader consistency in image interpretation,performance across subjects with varying cognitive statuses,and overall drug safety.

　　The clinical studies enrolled participants across different cognitive stages,including cognitively normal individuals,patients with mild cognitive impairment,and patients with Alzheimer's disease.Tau PET scans were used to observe tau protein aggregation in the brain and to assess the clinical value of the imaging agent for Alzheimer's disease-related detection.

　　Safety Profile

　　The safety of Tauklarify was evaluated in 1,734 subjects.The most commonly reported adverse reactions were all low in incidence:headache(0.7%),nausea(0.2%),injection site reactions(0.1%),dizziness(0.1%),and abdominal discomfort(0.1%).Overall tolerability was favorable.As Tauklarify contains the radionuclide fluorine-18,patients are exposed to a degree of ionizing radiation.Healthcare facilities must follow radiopharmaceutical handling protocols,avoid unnecessary repeat scans,and assess the clinical necessity of the procedure on an individual basis.

　　Warnings and Precautions

　　Regarding image interpretation,Tauklarify PET results cannot independently diagnose Alzheimer's disease and must be integrated with clinical presentation,cognitive evaluation,and other diagnostic information.Regarding radiation risk,facilities should adhere to radiopharmaceutical safety standards to minimize unnecessary exposure.Regarding hypersensitivity,allergic reactions may occur,and facilities should be prepared to recognize and manage such events.Regarding special populations,breastfeeding women should temporarily discontinue nursing after receiving Tauklarify,expressing and discarding breast milk for at least 4 hours.Regarding drug interactions,CYP1A2 inducers,including smoking,should be avoided for at least 7 days prior to Tauklarify administration.

　　Summary

　　Tauklarify(florquinitau F-18 injection)is a fluorine-18-labeled radiodiagnostic agent approved by the FDA for tau protein PET imaging in adult patients with cognitive impairment being evaluated for Alzheimer's disease.It provides auxiliary imaging information for clinical assessment and is positioned as a diagnostic tool rather than a therapeutic agent.